This study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of Astaxanthin on Alzheimer disease. The enrolled Alzheimer patients will take Astaxanthin or placebo for 1 year. We will follow up Mini-Mental State Examination, Cognitive Ability Screening Instrument, Clinical Dementia Rating, and Neuropsychiatric Inventory at the end of the study.
This study aims to examine the benefit of Astaxanthin as adjuvant therapy for Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
46
350 mg/capsule (2mg Astaxanthin)
Placebo
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Mini-Mental State Examination (MMSE)
All participants receive MMSE when they are enrolled, and follow up annually for a total of 3 years.
Time frame: 3 years
Cognitive Ability Screening Instrument (CASI)
All participants receive CASI when they are enrolled, and follow up annually for a total of 3 years.
Time frame: 3 years
Clinical Dementia Rating (CDR)
All participants receive CDR when they are enrolled, and follow up annually for a total of 3 years.
Time frame: 3 years
Neuropsychiatric Inventory (NPI)
All participants receive NPI when they are enrolled, and follow up annually for a total of 3 years.
Time frame: 3 years
Incidence of treatment-emergent adverse events [safety and tolerability]
Monitor possible adverse effects of Astaxanthin, namely bleeding, anemia, blood sugar, blood pressure, liver and renal functions.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.